Prostate Cancer in 2026: Focal Therapy, MRI-First Diagnosis, and Active Surveillance
DocSite AI Team
April 28, 2026
Prostate cancer used to be a binary choice: radical prostatectomy or radiation, both with substantial side effects. In 2026, MRI-first diagnosis, PSMA PET staging, focal therapy options, and refined active surveillance criteria mean far fewer men face that binary choice.
What's now standard in 2026
- Multiparametric MRI before biopsy — for elevated PSA, MRI directs the biopsy and reduces unnecessary procedures.
- PSMA PET-CT — far superior to bone scan + CT for detecting metastatic disease at staging and biochemical recurrence.
- Active surveillance for low-risk disease — preferred initial management for Gleason 6 (Grade Group 1) cancers, with MRI-driven monitoring.
The focal therapy story
- HIFU and cryotherapy — focal ablation of cancer-bearing zones, preserving the rest of the prostate.
- Best candidates — single-quadrant intermediate-risk disease, biopsy-MRI concordance, normal contralateral lobe.
- Trade-off — fewer urinary and sexual side effects, but oncological durability data still maturing; close MRI follow-up is essential.
What patients should ask
- Multidisciplinary opinion — urologist, radiation oncologist, and ideally focal-therapy specialist for intermediate-risk disease.
- Active surveillance literacy — for low-risk disease, treatment is often unnecessary; understand the MRI-driven follow-up protocol.
- Surgeon volume — robotic prostatectomy outcomes scale strongly with surgeon-specific case volume.
What this means for patients and practising clinicians
A 2026 prostate cancer journey looks very different from 2010. MRI-first diagnosis, PSMA PET staging, active surveillance for low-risk disease, and focal therapy for selected intermediate-risk cases are real options worth understanding before any treatment decision.
*This article was drafted by the DocSite AI Team and reviewed for clinical accuracy. It is general medical information, not personal medical advice. For decisions about your own care, please consult a qualified specialist on DocSite.*
Frequently Asked Questions
If I have low-risk prostate cancer, do I need treatment?
Often no immediate treatment is needed — active surveillance with regular MRI and PSA is now standard for most low-risk cases.
Is focal therapy for everyone?
No — careful selection by tumour location, MRI features, and biopsy concordance is essential. It's not appropriate for diffuse or high-risk disease.
How accurate is MRI for finding cancer?
Excellent for clinically significant cancer (Gleason ≥ 3+4). Some low-grade tumours remain MRI-invisible — biopsy still has a role.
Book a consult with your Specialist Urologist
Find practising urologists on DocSite and book directly — no middlemen, no paid rankings.
Find a Urologist